<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HFF514162E856414780E7EED46976A844" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4242 IH: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-06-21</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4242</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230621">June 21, 2023</action-date><action-desc><sponsor name-id="C001120">Mr. Crenshaw</sponsor> (for himself, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, and <cosponsor name-id="K000389">Mr. Khanna</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.</official-title></form><legis-body id="HC55A62A616774028914B41B54F01A076" style="OLC"> 
<section id="HCA5B8708F88A426184853D253025C124" section-type="section-one"><enum>1.</enum><header>Guidance on considerations for conducting clinical trials for psychedelic assisted therapy</header><text display-inline="no-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shallâ€”</text> <paragraph id="HD1245C70D34C48D78CF59EBD306225FB"><enum>(1)</enum><text>not later than 180 days after the date of enactment of this Act, issue for public comment draft guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how those seeking an investigational use exemption for such clinical trials should request interactive support by the Food and Drug Administration; and</text></paragraph> 
<paragraph id="HDA1DCF01439545668609EE68CDDCCD4C"><enum>(2)</enum><text>not later than 180 days after issuing such draft guidance, finalize such guidance.</text> </paragraph></section> </legis-body></bill>

